logo
Tatva Chintan Pharma Chem Ltd.
06 May 2023, 12:00AM
1006.65
-1.10%
ICICI Securities Limited
Tatva Chintan’s Q4FY23 revenue rose 26.4% YoY to Rs1.2bn as SDA revenue recovered to Rs0.5bn, up 41% YoY. However, gross profit margin dip of 400bps to 39.8% was disappointing (partly from a change in product mix) considering the company has guided for a sequential improvement in margins.
Tatva Chintan Pharma Chem Ltd. has gained 47.09% in the last 3 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended